Seizures News - LARVOL Sigma

Seizures	Welcome, Profile Billing Logout

«1 2 3 4 5 6 789 10 11 12 »

|||||||||| Trial completion: Quantifying Auditory Perceptual Learning Following Hearing Aid Fitting (clinicaltrials.gov) - Feb 19, 2014
P2, N=48, Completed, Sponsor: Department of Veterans Affairs
Recruiting --> Completed

|||||||||| Trial completion: Ketogenic Diet for Child Epilepsy and Seizure Control (clinicaltrials.gov) - Feb 19, 2014
P=N/A, N=0, Completed, Sponsor: National Institute of Neurological Disorders and Stroke (NINDS)
Recruiting --> Completed No longer recruiting --> Completed

|||||||||| Trial completion: Animal Assisted Therapy in a Pediatric Setting (clinicaltrials.gov) - Feb 12, 2014
P1/2, N=30, Completed, Sponsor: Children's Hospitals and Clinics of Minnesota
No longer recruiting --> Completed Active, not recruiting --> Completed

||||||||||  lacosamide / Generic mfg.
Enrollment closed:  A Trial to Evaluate the Efficacy and Safety of Adjunctive Therapy With Lacosamide in Adults With Partial-Onset Seizures (clinicaltrials.gov) -  Feb 3, 2014
P3, N=540, Active, not recruiting,  Sponsor: UCB Pharma SA
Active, not recruiting --> Completed Recruiting --> Active, not recruiting

||||||||||  labetalol / Generic mfg.
Trial initiation date:  LAMPET: Labetalol Versus Magnesium Sulfate (MgSO4) for the Prevention of Eclampsia Trial (clinicaltrials.gov) -  Jan 28, 2014
P2/3, N=8000, Suspended,  Sponsor: Baylor College of Medicine
Recruiting --> Active, not recruiting Initiation date: May 2003 --> Jun 2015

||||||||||  zonisamide / Generic mfg.
Trial completion, Monotherapy:  A Study to Evaluate the Safety and Efficacy of Zonisamide an Antiepileptic Drug as Monotherapy or Adjunctive Therapy in Treatment of Adult Patients With Partial, Generalized or Combined Seizures. (clinicaltrials.gov) -  Jan 22, 2014
P4, N=655, Completed,  Sponsor: Eisai Inc.
Initiation date: May 2003 --> Jun 2015 Active, not recruiting --> Completed

||||||||||  rufinamide / Generic mfg.
Trial completion:  A Long Term Extension Study of E2080 in Lennox-Gastaut Patients (clinicaltrials.gov) -  Jan 20, 2014
P3, N=54, Completed,  Sponsor: Eisai Co., Ltd.
Active, not recruiting --> Completed Active, not recruiting --> Completed

|||||||||| Biomarker, Enrollment change: Potential EEG Biomarkers and Antiepileptogenic Strategies for Epilepsy in TSC (clinicaltrials.gov) - Jan 15, 2014
P=N/A, N=40, Recruiting, Sponsor: University of Alabama at Birmingham
Active, not recruiting --> Completed N=30 --> 40

||||||||||  levetiracetam / Generic mfg.
Enrollment open:  A Dose-Escalation, Safety and Feasibility Study of Enteral LVT for Seizure Control in Pediatric CM (clinicaltrials.gov) -  Jan 15, 2014
P2, N=30, Recruiting,  Sponsor: University of Rochester
N=30 --> 40 Not yet recruiting --> Recruiting

|||||||||| Trial withdrawal, MRI: LAMA2-related Muscular Dystrophy Brain Study (clinicaltrials.gov) - Jan 14, 2014
P=N/A, N=0, Withdrawn, Sponsor: Cure CMD
Not yet recruiting --> Recruiting Not yet recruiting --> Withdrawn

|||||||||| Enrollment change, MRI: LAMA2-related Muscular Dystrophy Brain Study (clinicaltrials.gov) - Jan 14, 2014
P=N/A, N=0, Withdrawn, Sponsor: Cure CMD
Not yet recruiting --> Withdrawn N=25 --> 0

||||||||||  lacosamide / Generic mfg.
Enrollment change:  VERVE: eValuation of the Efficacy and toleRability of Vimpat When Added to lEvetiracetam (clinicaltrials.gov) -  Jan 13, 2014
P3, N=120, Completed,  Sponsor: UCB, Inc.
N=25 --> 0 N=300 --> 120

||||||||||  lacosamide / Generic mfg.
Trial completion:  VERVE: eValuation of the Efficacy and toleRability of Vimpat When Added to lEvetiracetam (clinicaltrials.gov) -  Jan 13, 2014
P3, N=120, Completed,  Sponsor: UCB, Inc.
N=300 --> 120 Active, not recruiting --> Completed

||||||||||  levetiracetam / Generic mfg.
Enrollment closed:  An Open Label Study of L059 (Levetiracetam) in Japanese Epilepsy Subjects With Generalized Tonic-clonic Seizures (clinicaltrials.gov) -  Jan 9, 2014
P3, N=44, Active, not recruiting,  Sponsor: UCB, Inc.
Active, not recruiting --> Completed Recruiting --> Active, not recruiting

|||||||||| Enrollment change: Double Blind, Crossover Study of Fish Oil [EPA and DHA] for Intractable Partial Seizures (clinicaltrials.gov) - Jan 7, 2014
P2, N=24, Completed, Sponsor: National Center for Complementary and Alternative Medicine (NCCAM)
Recruiting --> Active, not recruiting N=30 --> 24

|||||||||| Trial completion: Double Blind, Crossover Study of Fish Oil [EPA and DHA] for Intractable Partial Seizures (clinicaltrials.gov) - Jan 7, 2014
P2, N=24, Completed, Sponsor: National Center for Complementary and Alternative Medicine (NCCAM)
N=30 --> 24 Recruiting --> Completed

|||||||||| Trial termination: IVIG Treatment for Refractory Immune-Related Adult Epilepsy (clinicaltrials.gov) - Jan 4, 2014
P2, N=20, Terminated, Sponsor: Emory University
Recruiting --> Completed Enrolling by invitation --> Terminated; Futility criteria, unable for Phase 2 of study, & phase 1 was terminated.

|||||||||| Enrollment change: IVIG Treatment for Refractory Immune-Related Adult Epilepsy (clinicaltrials.gov) - Jan 4, 2014
P2, N=20, Terminated, Sponsor: Emory University
Enrolling by invitation --> Terminated; Futility criteria, unable for Phase 2 of study, & phase 1 was terminated. N=50 --> 20

|||||||||| Trial initiation date: Evaluating the Efficacy of Magnetic Seizure Therapy in Treatment Resistant Depression. (clinicaltrials.gov) - Dec 18, 2013
P=N/A, N=200, Not yet recruiting, Sponsor: Centre for Addiction and Mental Health
N=50 --> 20 Initiation date: Sep 2013 --> Sep 2014

|||||||||| Enrollment closed: Seizure Detection and Automatic Magnet Mode Performance Study (clinicaltrials.gov) - Dec 11, 2013
P=N/A, N=35, Active, not recruiting, Sponsor: Cyberonics, Inc.
Initiation date: Sep 2013 --> Sep 2014 Recruiting --> Active, not recruiting

||||||||||  phenobarbital / Generic mfg., midazolam hydrochloride / Generic mfg.
Enrollment closed:  The Impact of Electroencephalographic (EEG) Seizure Treatment in Neonatal Encephalopathy (clinicaltrials.gov) -  Dec 11, 2013
P=N/A, N=40, Active, not recruiting,  Sponsor: Washington University School of Medicine
Recruiting --> Active, not recruiting Not yet recruiting --> Active, not recruiting

||||||||||  lacosamide / Generic mfg.
Trial termination:  VICTOR: Hormonal and Lipid Levels in Male Subjects After a Switch From Carbamazepine to Lacosamide (clinicaltrials.gov) -  Dec 9, 2013
P3, N=11, Terminated,  Sponsor: UCB, Inc.
Not yet recruiting --> Active, not recruiting Recruiting --> Terminated; Slow progress despite recruitment boosting efforts e.g., expert advice obtained from leading study center Investigators; decision thus made to terminate.

||||||||||  lacosamide / Generic mfg.
Enrollment change:  VICTOR: Hormonal and Lipid Levels in Male Subjects After a Switch From Carbamazepine to Lacosamide (clinicaltrials.gov) -  Dec 9, 2013
P3, N=11, Terminated,  Sponsor: UCB, Inc.
Recruiting --> Terminated; Slow progress despite recruitment boosting efforts e.g., expert advice obtained from leading study center Investigators; decision thus made to terminate. N=28 --> 11

||||||||||  oxcarbazepine / Generic mfg.
Enrollment change:  Efficacy, Safety and Tolerability of TRI476 (Oxcarbazepine) in Children With Inadequately Controlled Partial Onset Seizures (clinicaltrials.gov) -  Dec 5, 2013
P2/3, N=99, Completed,  Sponsor: Novartis Pharmaceuticals
N=28 --> 11 N=200 --> 99

||||||||||  oxcarbazepine / Generic mfg.
Trial completion:  Efficacy, Safety and Tolerability of TRI476 (Oxcarbazepine) in Children With Inadequately Controlled Partial Onset Seizures (clinicaltrials.gov) -  Dec 5, 2013
P2/3, N=99, Completed,  Sponsor: Novartis Pharmaceuticals
N=200 --> 99 Active, not recruiting --> Completed

||||||||||  Vanquix (diazepam auto-injector) / Pfizer
Enrollment closed:  Efficacy and Safety of Diazepam in the Management of Refractory Epilepsy in Selected Patients Who Require Intermittent Medical Intervention for Acute Repetitive Seizures. (clinicaltrials.gov) -  Dec 3, 2013
P3, N=234, Active, not recruiting,  Sponsor: Pfizer
Active, not recruiting --> Completed Recruiting --> Active, not recruiting

||||||||||  zonisamide / Generic mfg.
Enrollment change:  Efficacy and Safety of an add-on Treatment With Zonisamide in Adults With Focal Epileptic Seizures With or Without Secondary Generalization (clinicaltrials.gov) -  Nov 18, 2013
P4, N=157, Terminated,  Sponsor: Eisai GmbH
Recruiting --> Active, not recruiting N=200 --> 157

||||||||||  levetiracetam / Generic mfg.
New P2 trial:  A Dose-Escalation, Safety and Feasibility Study of Enteral LVT for Seizure Control in Pediatric CM (clinicaltrials.gov) -  Nov 11, 2013
P2, N=30, Recruiting,  Sponsor: University of Rochester

||||||||||  levetiracetam / Generic mfg.
Trial completion:  An Open Label Study of Levetiracetam in Japanese Pediatric Patients With Partial Seizures (clinicaltrials.gov) -  Oct 29, 2013
P3, N=73, Completed,  Sponsor: UCB, Inc.
N=200 --> 157 Active, not recruiting --> Completed

||||||||||  zonisamide / Generic mfg., sodium valproate / Generic mfg.
Trial completion:  Comparing The Effect On Cognition Of Adjunctive Therapy With Zonisamide Versus Sodium Valproate (clinicaltrials.gov) -  Oct 29, 2013
P4, N=2, Completed,  Sponsor: Eisai Limited
Active, not recruiting --> Completed Terminated --> Completed

|||||||||| Enrollment change: PuLsE 2-Observational Long-Term Effectiveness Follow-Up Study of PuLsE 1 (clinicaltrials.gov) - Oct 28, 2013
P=N/A, N=81, Active, not recruiting, Sponsor: Cyberonics, Inc.
Terminated --> Completed N=121 --> 81

|||||||||| Enrollment closed: Magnetic Seizure Therapy (MST) for Treatment Resistant Major Depression (clinicaltrials.gov) - Oct 27, 2013
P3, N=30, Active, not recruiting, Sponsor: University Hospital, Bonn
N=121 --> 81 Recruiting --> Active, not recruiting

||||||||||  levetiracetam / Generic mfg.
New P4 trial:  Seizure Prophylaxis in Aneurysm Repair (clinicaltrials.gov) -  Oct 27, 2013
P4, N=266, Recruiting,  Sponsor: Indiana University

||||||||||  levetiracetam / Generic mfg.
Enrollment open:  Seizure Prophylaxis in Aneurysm Repair (clinicaltrials.gov) -  Oct 27, 2013
P4, N=266, Recruiting,  Sponsor: Indiana University
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting

|||||||||| Trial suspension, Intubation: Early Versus Late Intubation Trial in Physician Manned Emergency Medical Services (clinicaltrials.gov) - Oct 24, 2013
P=N/A, N=500, Suspended, Sponsor: Norwegian Air Ambulance Foundation
Not yet recruiting --> Recruiting Recruiting --> Suspended

||||||||||  lacosamide / Generic mfg.
New P2 trial:  A Study to Investigate the Safety and Efficacy of Lacosamide Added to the Patients Current Therapy in Patients Aged 1 Month to Less Than 18 Years Old With Epilepsy Syndromes Associated With Generalized Seizures. (clinicaltrials.gov) -  Oct 23, 2013
P2, N=50, Recruiting,  Sponsor: UCB, Inc.

||||||||||  lacosamide / Generic mfg.
Enrollment open:  A Study to Investigate the Safety and Efficacy of Lacosamide Added to the Patients Current Therapy in Patients Aged 1 Month to Less Than 18 Years Old With Epilepsy Syndromes Associated With Generalized Seizures. (clinicaltrials.gov) -  Oct 20, 2013
P2, N=50, Recruiting,  Sponsor: UCB, Inc.
Recruiting --> Suspended Not yet recruiting --> Recruiting

||||||||||  Potiga (retigabine) / Bausch Health, GSK
Enrollment change:  Assessment of the Efficacy and Safety of 2 Doses of Retigabine Immediate Release (900 mg/Day and 600 mg/Day) Used as Adjunctive Therapy in Adult Asian Subjects With Drug-resistant Partial-onset Seizures (clinicaltrials.gov) -  Oct 9, 2013
P3, N=76, Terminated,  Sponsor: GlaxoSmithKline
Not yet recruiting --> Recruiting N=37 --> 76

|||||||||| Enrollment change, IO biomarker: Clinical and Immunological Investigations of Subtypes of Autism (clinicaltrials.gov) - Oct 8, 2013
P=N/A, N=546, Completed, Sponsor: National Institute of Mental Health (NIMH)
N=37 --> 76 N=800 --> 546

|||||||||| Trial completion, IO biomarker: Clinical and Immunological Investigations of Subtypes of Autism (clinicaltrials.gov) - Oct 8, 2013
P=N/A, N=546, Completed, Sponsor: National Institute of Mental Health (NIMH)
N=800 --> 546 Recruiting --> Completed

||||||||||  phenobarbital / Generic mfg.
Enrollment closed:  Evaluation Phenobarbital as Adjunctive Therapy in Participants With Partial Onset Seizures (clinicaltrials.gov) -  Oct 7, 2013
P3, N=345, Active, not recruiting,  Sponsor: West-Ward Pharmaceutical
Recruiting --> Completed Recruiting --> Active, not recruiting

||||||||||  levetiracetam / Generic mfg., carbamazepine / Generic mfg.
New P3 trial, Monotherapy:  Open-label, Randomized, Active-controlled Study of LEV Used as Monotherapy in Patients With Partial-Onset Seizures (clinicaltrials.gov) -  Sep 29, 2013
P3, N=436, Recruiting,  Sponsor: UCB Pharma SA

||||||||||  Aptiom (eslicarbazepine) / Sumitomo Dainippon, BIAL
Trial completion, Monotherapy:  Safety and Efficacy of Eslicarbazepine Acetate Monotherapy in Subjects With Partial Epilepsy Not Well Controlled by Current Antiepileptic Drugs (clinicaltrials.gov) -  Sep 24, 2013
P3, N=174, Completed,  Sponsor: Sunovion
Recruiting --> Active, not recruiting Active, not recruiting --> Completed

|||||||||| Trial initiation date, Intubation: Early Versus Late Intubation Trial in Physician Manned Emergency Medical Services (clinicaltrials.gov) - Sep 23, 2013
P=N/A, N=500, Suspended, Sponsor: Norwegian Air Ambulance Foundation
Active, not recruiting --> Completed Initiation date: Feb 2013 --> Sep 2013

|||||||||| Surgery: Effect of Music Therapy on Cognitive Recovery (clinicaltrials.gov) - Sep 18, 2013
P=N/A, N=60, Not yet recruiting, Sponsor: Seton Family of Hospitals

||||||||||  levetiracetam / Generic mfg.
Enrollment closed:  A Double-blind, Placebo-controlled Study of Levetiracetam in Epilepsy Patients With Generalized Tonic-clonic Seizures (Except Partial Seizures Evolving to Secondarily Generalized Seizures) (clinicaltrials.gov) -  Sep 15, 2013
P3, N=276, Active, not recruiting,  Sponsor: UCB Japan Co. Ltd.
Initiation date: Feb 2013 --> Sep 2013 Recruiting --> Active, not recruiting

|||||||||| Trial completion: Preventing Depression in People With Epilepsy: an Extension of Project UPLIFT (clinicaltrials.gov) - Sep 9, 2013
P=N/A, N=130, Completed, Sponsor: Emory University
Recruiting --> Active, not recruiting Not yet recruiting --> Completed

||||||||||  Potiga (retigabine) / Bausch Health, GSK
Trial termination:  Assessment of the Efficacy and Safety of 2 Doses of Retigabine Immediate Release (900 mg/Day and 600 mg/Day) Used as Adjunctive Therapy in Adult Asian Subjects With Drug-resistant Partial-onset Seizures (clinicaltrials.gov) -  Sep 4, 2013
P3, N=76, Terminated,  Sponsor: GlaxoSmithKline
Not yet recruiting --> Completed Recruiting --> Terminated; Registration of the medicine is no longer being pursued in South Korea, Taiwan or Vietnam

||||||||||  levetiracetam / Generic mfg.
New P4 trial:  SPLASH - Pilot: Seizure Prophylaxis With Levetiracetam in Aneurysmal Subarachnoid Hemorrhage - Pilot Study (clinicaltrials.gov) -  Sep 3, 2013
P4, N=36, Not yet recruiting,  Sponsor: Vanderbilt University

||||||||||  lacosamide / Generic mfg.
Enrollment change:  Trial to Assess Lacosamide as the First add-on Anti-epileptic Drug Treatment in Patients With Partial-onset Seizures (clinicaltrials.gov) -  Aug 28, 2013
P4, N=461, Completed,  Sponsor: UCB, Inc.
Recruiting --> Terminated; Registration of the medicine is no longer being pursued in South Korea, Taiwan or Vietnam N=656 --> 461



	Diseases Companies Products Productz Mechanisms of Action Sites